These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 10921528)
21. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Nowak Ł; Adamczak M; Wiecek A Am J Hypertens; 2005 Nov; 18(11):1470-5. PubMed ID: 16280284 [TBL] [Abstract][Full Text] [Related]
22. The human sympathetic nervous system: its relevance in hypertension and heart failure. Parati G; Esler M Eur Heart J; 2012 May; 33(9):1058-66. PubMed ID: 22507981 [TBL] [Abstract][Full Text] [Related]
23. [Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension]. Mancia G; Seravalle G; Grassi G Ann Ital Med Int; 1997; 12(4):217-22. PubMed ID: 9773576 [TBL] [Abstract][Full Text] [Related]
24. Biochemical evidence of sympathetic hyperactivity in human hypertension. Esler M; Ferrier C; Lambert G; Eisenhofer G; Cox H; Jennings G Hypertension; 1991 Apr; 17(4 Suppl):III29-35. PubMed ID: 2013490 [TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension. Esler M; Lambert G; Esler D; Ika Sari C; Guo L; Jennings G J Hypertens; 2020 Aug; 38(8):1488-1495. PubMed ID: 32195820 [TBL] [Abstract][Full Text] [Related]
27. Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. Esler M J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S24-8. PubMed ID: 8642801 [TBL] [Abstract][Full Text] [Related]
28. Antihypertensive drugs and sympathetic nervous system. Rabbia F; Martini G; Cat Genova G; Milan A; Chiandussi L; Veglio F Clin Exp Hypertens; 2001; 23(1-2):101-11. PubMed ID: 11270578 [TBL] [Abstract][Full Text] [Related]
29. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Mancia G; Grassi G; Giannattasio C; Seravalle G Hypertension; 1999 Oct; 34(4 Pt 2):724-8. PubMed ID: 10523349 [TBL] [Abstract][Full Text] [Related]
31. The sympathetic nervous system in hypertension: back to the future? Esler M Curr Hypertens Rep; 2015 Feb; 17(2):11. PubMed ID: 25680900 [TBL] [Abstract][Full Text] [Related]
32. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. Kaye DM; Lambert GW; Lefkovits J; Morris M; Jennings G; Esler MD J Am Coll Cardiol; 1994 Mar; 23(3):570-8. PubMed ID: 8113536 [TBL] [Abstract][Full Text] [Related]
33. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension. Esler M Exp Physiol; 2011 Jul; 96(7):611-22. PubMed ID: 21551268 [TBL] [Abstract][Full Text] [Related]
34. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369 [TBL] [Abstract][Full Text] [Related]
35. Dissociation between sympathetic nerve traffic and sympathetically mediated vascular tone in normotensive human obesity. Agapitov AV; Correia ML; Sinkey CA; Haynes WG Hypertension; 2008 Oct; 52(4):687-95. PubMed ID: 18695151 [TBL] [Abstract][Full Text] [Related]
36. Sympathetic activity, blood pressure variability and end organ damage in hypertension. Mancia G; Di Rienzo M; Parati G; Grassi G J Hum Hypertens; 1997 Aug; 11 Suppl 1():S3-8. PubMed ID: 9321734 [TBL] [Abstract][Full Text] [Related]
37. Noradrenaline spillover and microneurography measurements in patients with primary hypertension. Jennings GL J Hypertens Suppl; 1998 Aug; 16(3):S35-8. PubMed ID: 9747908 [TBL] [Abstract][Full Text] [Related]
38. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Lambert GW; Kaye DM; Lefkovits J; Jennings GL; Turner AG; Cox HS; Esler MD Circulation; 1995 Oct; 92(7):1813-8. PubMed ID: 7545554 [TBL] [Abstract][Full Text] [Related]
39. The sympathetic nervous system in the pathogenesis of hypertension. Rahn KH; Barenbrock M; Hausberg M J Hypertens Suppl; 1999 Aug; 17(3):S11-4. PubMed ID: 10489093 [TBL] [Abstract][Full Text] [Related]
40. How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. Konrady AO; Kasherininov YR; Shavarov AA; Shavarova EK; Vachrameeva NV; Krutikov AN; Smirnova EV; Shlyakhto EV J Hum Hypertens; 2006 Jun; 20(6):398-406. PubMed ID: 16543910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]